

CLAIMS

1. A heterodimeric antibody comprising:
 - a) a first monomer comprising SEQ ID NO:468;
 - b) a second monomer comprising SEQ ID NO:469; and
 - c) a light chain comprising SEQ ID NO:470.
2. A nucleic acid composition comprising:
 - a) a first nucleic acid sequence encoding SEQ ID NO:468;
 - b) a second nucleic acid sequence encoding SEQ ID NO:469; and
 - c) a third nucleic acid sequence encoding SEQ ID NO:470.
3. An expression vector composition comprising:
 - a) a first expression vector comprising a first nucleic acid sequence encoding SEQ ID NO:468;
 - b) a second expression vector comprising a second nucleic acid sequence encoding SEQ ID NO:469; and
 - c) a third expression vector comprising a third nucleic acid sequence encoding SEQ ID NO:470.
4. A host cell comprising the nucleic acid composition of claim 2.
5. A host cell comprising the expression vector composition of claim 3.
6. A method of making the heterodimeric antibody of claim 1 comprising culturing the host cell of claim 4 or claim 5 under conditions wherein said antibody is expressed, and recovering said antibody.
7. A heterodimeric antibody of claim 1 for use in treating cancer.
8. Use of a heterodimeric antibody according to claim 1, in the manufacture of a medicament for the treatment of a hematopoietic cancer.
9. The use according to claim 8, wherein said hematopoietic cancer is a B cell lymphoma or leukemia.

10. The use according to claim 9, wherein said B cell lymphoma or leukemia is selected from the group consisting of non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and chronic myeloid leukemia (CML).